AIM raises ~ $8.5M via warrant exercises and private placements; regains NYSE compliance
AI Summary
AIM ImmunoTech completed a May warrant-exercise inducement (~$3.5M) and two concurrent private placements/issuances on May 21 (~$2.4M) and June 10 (~$2.6M), raising aggregate gross proceeds of roughly $8.5M and issuing ~10.07M common shares plus pre-funded and Class I/J warrants. The company says these transactions restored stockholders' equity above the NYSE American $6.0M minimum, so the '.BC' noncompliance indicator will be removed; however the financings created a material warrant overhang (new warrants convertible into ~27.04M shares). Timing: Same-day dilution is possible if holders convert, but the press release does not provide a firm first-dilution date.
Positives
- Regained NYSE American compliance; '.BC' indicator to be removed
- Completed cash warrant exercises and two private placements raising ~ $8.5M gross proceeds
- Closings completed (May 21 and June 10, 2026) that management says restored stockholders' equity above the $6.0M minimum
Negatives
- Issued ~10.07M common shares across the May 21 and June 10 closings (immediate share count increase)
- New Class I and Class J warrants plus pre-funded warrants create potential issuance of ~27.04M additional shares
- Material warrant overhang that can cause further dilution if exercised
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: date unknown
Dilution status
potential
Dilution timing
Dilution status: Undetermined
Trigger type
conversion
Trigger date
May 7, 2026